AnaptysBio (ANAB) PT Lowered to $52 at H.C. Wainwright

Go back to AnaptysBio (ANAB) PT Lowered to $52 at H.C. Wainwright

AnaptysBio (ANAB) PT Lowered to $45 at Leerink Partners

November 6, 2024 5:58 AM EST

Leerink Partners analyst David Risinger lowered the price target on AnaptysBio (NASDAQ: ANAB) to $45.00 (from $47.00) while maintaining a Outperform rating.

The analyst comments " Bottom Line: ANAB reported 3Q results and stated that there have been no blinded safety issues to date with either its BTLA... More

AnaptysBio, Inc. (ANAB) Tops Q3 EPS by 56c

November 5, 2024 4:58 PM EST

AnaptysBio, Inc. (NASDAQ: ANAB) reported Q3 EPS of ($1.14), $0.56 better than the analyst estimate of ($1.70). Revenue for the quarter came in at $30.02 million versus the consensus estimate of $6.92 million.

For earnings history and earnings-related data on AnaptysBio, Inc. (ANAB) click here.

... More

Anaptysbio (ANAB) Files $500M Mixed Shelf

November 5, 2024 4:30 PM EST

Anaptysbio (NASDAQ: ANAB) has filed $500,000,000 mixed shelf of:

Common Stock, Preferred Stock, Debt Securities, Warrants, Subscription Rights and Units

... More